RU2018102365A3 - - Google Patents

Download PDF

Info

Publication number
RU2018102365A3
RU2018102365A3 RU2018102365A RU2018102365A RU2018102365A3 RU 2018102365 A3 RU2018102365 A3 RU 2018102365A3 RU 2018102365 A RU2018102365 A RU 2018102365A RU 2018102365 A RU2018102365 A RU 2018102365A RU 2018102365 A3 RU2018102365 A3 RU 2018102365A3
Authority
RU
Russia
Application number
RU2018102365A
Other languages
Russian (ru)
Other versions
RU2018102365A (ru
RU2734418C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2018102365A publication Critical patent/RU2018102365A/ru
Publication of RU2018102365A3 publication Critical patent/RU2018102365A3/ru
Application granted granted Critical
Publication of RU2734418C2 publication Critical patent/RU2734418C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
RU2018102365A 2015-06-23 2016-06-22 Новые гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их RU2734418C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1555752A FR3037957B1 (fr) 2015-06-23 2015-06-23 Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR1555752 2015-06-23
PCT/EP2016/064433 WO2016207225A1 (en) 2015-06-23 2016-06-22 New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them

Publications (3)

Publication Number Publication Date
RU2018102365A RU2018102365A (ru) 2019-07-23
RU2018102365A3 true RU2018102365A3 (enExample) 2019-09-23
RU2734418C2 RU2734418C2 (ru) 2020-10-16

Family

ID=54608634

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018102365A RU2734418C2 (ru) 2015-06-23 2016-06-22 Новые гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их

Country Status (43)

Country Link
US (2) US10227358B2 (enExample)
EP (1) EP3313851B1 (enExample)
JP (1) JP6741697B2 (enExample)
KR (1) KR102718253B1 (enExample)
CN (1) CN107709333B (enExample)
AR (1) AR105103A1 (enExample)
AU (1) AU2016282836B2 (enExample)
BR (1) BR112017027414B1 (enExample)
CA (1) CA2990088C (enExample)
CL (1) CL2017003258A1 (enExample)
CO (1) CO2017012786A2 (enExample)
CR (1) CR20170564A (enExample)
CU (1) CU20170160A7 (enExample)
CY (1) CY1122542T1 (enExample)
DK (1) DK3313851T3 (enExample)
EA (1) EA033266B1 (enExample)
EC (1) ECSP17081744A (enExample)
ES (1) ES2759480T3 (enExample)
FR (1) FR3037957B1 (enExample)
GE (1) GEP20207074B (enExample)
HK (1) HK1249506A1 (enExample)
HR (1) HRP20200107T1 (enExample)
HU (1) HUE047889T2 (enExample)
IL (1) IL256270A (enExample)
JO (1) JO3675B1 (enExample)
MA (1) MA42239B1 (enExample)
MD (1) MD3313851T2 (enExample)
MX (1) MX372716B (enExample)
MY (1) MY190561A (enExample)
PE (1) PE20180742A1 (enExample)
PH (1) PH12017502246A1 (enExample)
PL (1) PL3313851T3 (enExample)
PT (1) PT3313851T (enExample)
RS (1) RS59904B1 (enExample)
RU (1) RU2734418C2 (enExample)
SI (1) SI3313851T1 (enExample)
SV (1) SV2017005587A (enExample)
TN (1) TN2017000511A1 (enExample)
TW (1) TWI604844B (enExample)
UA (1) UA122228C2 (enExample)
UY (1) UY36736A (enExample)
WO (1) WO2016207225A1 (enExample)
ZA (1) ZA201708460B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2017300738A1 (en) 2016-07-22 2019-02-07 Les Laboratoires Servier Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof
WO2018126898A1 (zh) * 2017-01-05 2018-07-12 河南美泰宝生物制药有限公司 噻吩并嘧啶衍生物、其制备方法及在制备抗肿瘤药物中的应用
GEP20227372B (en) * 2017-01-06 2022-04-25 Novartis Ag Combination of a mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof
UY37560A (es) 2017-01-06 2018-07-31 Servier Lab Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
ES2971466T3 (es) * 2017-06-22 2024-06-05 Servier Lab Combinación de un inhibidor de Mcl-1 y un tratamiento estándar de atención para cánceres hematológicos, usos y composiciones farmacéuticas de la misma
SG10202106345VA (en) 2017-08-15 2021-07-29 Abbvie Inc Macrocyclic mcl-1 inhibitors and methods of use
BR112020003163A2 (pt) * 2017-08-15 2020-09-15 AbbVie Deutschland GmbH & Co. KG inibidores macrocíclicos de mcl-1 e métodos de uso
CN111372936B (zh) * 2017-11-23 2022-12-02 北京赛林泰医药技术有限公司 Mcl-1选择性抑制剂及其制备和用途
CN108424417B (zh) * 2017-12-21 2019-09-20 河南真实生物科技有限公司 噻吩并嘧啶衍生物、其制备方法及在制备抗肿瘤药物中的应用
CN110964034B (zh) * 2018-09-29 2022-04-12 江苏恒瑞医药股份有限公司 嘧啶并噻吩类衍生物、其制备方法及其在医药上的应用
TWI849001B (zh) 2018-11-14 2024-07-21 法商施維雅藥廠 Mcl-1抑制劑及米哚妥林(midostaurin)之組合,其用途及醫藥組合物
CN111187277B (zh) * 2018-11-14 2022-04-12 江苏恒瑞医药股份有限公司 噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用
LT3891156T (lt) * 2018-12-06 2023-12-27 Les Laboratoires Servier Tienopirimidino, kaip mcl-1 inhibitoriaus, naujos kristalinės formos
UY38700A (es) 2019-05-20 2020-12-31 Novartis Ag Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso
TW202114682A (zh) 2019-06-17 2021-04-16 法商施維雅藥廠 Mcl-1抑制劑與乳癌標準療法之組合,其用途及醫藥組合物
CN114746428B (zh) * 2019-10-03 2025-05-16 加利福尼亚技术学院 Mcl1抑制剂及其应用
US20240042051A1 (en) 2020-11-24 2024-02-08 Francesca Rocchetti Mcl-1 inhibitor antibody-drug conjugates and methods of use
WO2022216946A1 (en) * 2021-04-07 2022-10-13 California Institute Of Technology Mcl1 inhibitors and uses thereof
WO2022261310A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-body drug conjugates
CN117651554A (zh) 2021-06-11 2024-03-05 吉利德科学公司 Mcl-1抑制剂与抗癌剂的组合
CN113651663B (zh) * 2021-08-20 2024-03-29 浙大宁波理工学院 一种氘代芳香羰基类化合物的制备方法
WO2023057484A1 (en) 2021-10-06 2023-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy
WO2023225359A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
WO2025111450A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd74 antibody-drug conjugates and methods of use thereof
WO2025111431A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd7 antibody-drug conjugates and methods of use thereof
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗il-1rap結合結構域及其抗體-藥物偶聯物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
EP1675861B1 (en) * 2003-08-29 2015-12-23 Vernalis (R&D) Ltd. Pyrimidothiophene compounds
UA100262C2 (uk) * 2008-03-05 2012-12-10 Метилген Інк. Інгібітори активності протеїнтирозинкінази
CN102464667B (zh) * 2010-11-03 2014-06-04 中国科学院上海药物研究所 一类五元杂环并嘧啶类化合物及其制备方法和用途
AR090037A1 (es) * 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
MX372716B (es) 2020-05-28
PL3313851T3 (pl) 2020-05-18
PT3313851T (pt) 2020-01-06
MY190561A (en) 2022-04-27
SI3313851T1 (sl) 2020-03-31
PH12017502246B1 (en) 2018-05-28
UA122228C2 (uk) 2020-10-12
HK1254657A1 (en) 2019-07-26
CN107709333B (zh) 2021-01-01
RS59904B1 (sr) 2020-03-31
RU2018102365A (ru) 2019-07-23
SV2017005587A (es) 2018-04-11
US20190161496A1 (en) 2019-05-30
US20180170947A1 (en) 2018-06-21
CU20170160A7 (es) 2018-05-08
EA201890125A1 (ru) 2018-06-29
CO2017012786A2 (es) 2018-04-10
PH12017502246A1 (en) 2018-05-28
PE20180742A1 (es) 2018-04-27
UY36736A (es) 2016-12-30
AU2016282836B2 (en) 2020-07-09
MD3313851T2 (ro) 2020-02-29
TWI604844B (zh) 2017-11-11
HUE047889T2 (hu) 2020-05-28
GEP20207074B (en) 2020-03-10
AR105103A1 (es) 2017-09-06
AU2016282836A1 (en) 2018-01-18
CR20170564A (es) 2018-02-20
CL2017003258A1 (es) 2018-06-01
ES2759480T3 (es) 2020-05-11
IL256270A (en) 2018-02-28
JO3675B1 (ar) 2020-08-27
US10711010B2 (en) 2020-07-14
CA2990088A1 (en) 2016-12-29
ZA201708460B (en) 2021-06-30
CN107709333A (zh) 2018-02-16
CA2990088C (en) 2021-04-13
BR112017027414B1 (pt) 2023-12-19
KR20180019223A (ko) 2018-02-23
KR102718253B1 (ko) 2024-10-16
BR112017027414A2 (pt) 2018-08-28
FR3037957A1 (enExample) 2016-12-30
EA033266B1 (ru) 2019-09-30
WO2016207225A1 (en) 2016-12-29
DK3313851T3 (da) 2020-01-27
NZ738455A (en) 2024-03-22
EP3313851B1 (en) 2019-11-06
JP6741697B2 (ja) 2020-08-19
CY1122542T1 (el) 2021-01-27
ECSP17081744A (es) 2018-02-28
FR3037957B1 (fr) 2019-01-25
EP3313851A1 (en) 2018-05-02
TN2017000511A1 (en) 2019-04-12
TW201709911A (zh) 2017-03-16
RU2734418C2 (ru) 2020-10-16
US10227358B2 (en) 2019-03-12
MX2017016997A (es) 2018-09-07
MA42239B1 (fr) 2020-02-28
HRP20200107T1 (hr) 2020-04-03
JP2018522855A (ja) 2018-08-16
HK1249506A1 (zh) 2018-11-02

Similar Documents

Publication Publication Date Title
BE2015C047I2 (enExample)
CN303067893S (enExample)
BR0002402B1 (enExample)
BR0000126B1 (enExample)
BR0000695B1 (enExample)
BR0000763F1 (enExample)
BR0001536B1 (enExample)
BR0001684B1 (enExample)
BR0001810B1 (enExample)
BR0002033B1 (enExample)
CN303069369S (enExample)
BR0002435B1 (enExample)
BR0002694B1 (enExample)
BR0002802B1 (enExample)
BR0002874B1 (enExample)
BR0003166B1 (enExample)
BR0003189B1 (enExample)
BR0003208B1 (enExample)
BR0003401B1 (enExample)
BR0003686B1 (enExample)
BR0003746B1 (enExample)
BR0003751B1 (enExample)
BR0003928B1 (enExample)
BR0004687B1 (enExample)
BR0005041B1 (enExample)